We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
MaxCyte
Commercial licence agreement with KSQHutchison China MediTech
Elunate (fruquintinib) secures China NRDL listingMereo BioPharma
Setrusumab ready to advance into pivotal studiesFutura Medical
Elegant and effective treatment for Erectile DysfunctionMaxCyte
And yet another commercial licence agreementBerGenBio
Bemcentinib NSCLC data continues to impressBonesupport
A second consecutive quarter of record revenueHutchison China MediTech
Acceptance of surufatintib China NDA in epNETMereo BioPharma
Setrusumab set to advanceMaxCyte
Third cohort in CARMA Phase I initiated